Randolph Corteling's Biography

• Home
• |
• Registration
• |
• Submissions
  • Submission Guidelines
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Short Courses
  • Training Courses
• |
• Co-Located Conferences
• |
• Media
• |

An Exosome-based Drug Delivery Platform Derived From an Immortalized Human Neural Stem Cell (hNSC) Line

Thursday, 28 March 2019 at 17:00

Add to Calendar ▼2019-03-28 17:00:002019-03-28 18:00:00Europe/LondonAn Exosome-based Drug Delivery Platform Derived From an Immortalized Human Neural Stem Cell (hNSC) LineExtracellular Vesicle-based Dx and Rx Summit in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

To ensure the scale required for clinical research and commercialization producer cell immortalization and clonal isolation is a practical strategy to produce consistent, functionally bioactive exosomes for use as therapeutic agents. Immortalization ensures production stability and reduces the need for equivalence testing.

CTX0E03 is a conditionally immortalized human neural stem cell line which has been manufactured to clinical-grade (GMP) standards using a 3-tier banking strategy and is currently in Phase II clinical evaluation for disability after stroke. Using the conditioned media produced during GMP manufacture, we have shown that CTX0E03 is an abundant producer of exosomes which can be readily isolated and purified at scale.

The CTX cell line can also be rapidly and efficiently modified to direct the expression of a variety of cargoes within the secreted EV population, whilst maintaining the key immortalized stem cell characteristics of the parental cell line.  The natural tissue tropism of CTX-derived exosomes can then be exploited to deliver loaded cargoes to target cells.